Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients
Henrik Møller(Danish Institute for Quality and Accreditation in Healthcare), James Spicer(King's College London), Peter Vedsted(Aarhus University), Thomas Round(King's College London), Matthew Callister(University of Leeds), Erik Jakobsen(Aarhus University Hospital), David Baldwin(University of Nottingham), Daniela Tataru(NHS Digital), Victoria H. Coupland(Public Health England), Richard Sullivan(Precision Spine (United States)), Michael Peake(University of Leicester), Anders Mellemgaard(AstraZeneca (United Kingdom))
Cited by 44
Related Papers
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
|The Lancet Oncology|2014|948
Effect of Obesity on Prognosis After Early-Stage Breast Cancer
|Journal of Clinical Oncology|2010|600
The expanding role of primary care in cancer control
|The Lancet Oncology|2015|544
Detection and characterization of lung cancer using cell-free DNA fragmentomes
|Nature Communications|2021|458